Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT05025059

Exercise During Chemotherapy in Older Women With Stage I-III Breast Cancer

This clinical trial evaluates the feasibility of exercise during chemotherapy in older women with stage I-III breast cancer. Previous studies have reported that exercise may reduce the chemotherapy-toxicity risk. This trial may help researchers learn if engaging in a physical activity program is feasible in patients receiving chemotherapy for breast cancer.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

About this study

PRIMARY OBJECTIVE:

I. Determine the feasibility of implementing a home-based exercise intervention in older adults receiving chemotherapy for early-stage breast cancer.

SECONDARY OBJECTIVES:

I. Describe and determine the incidence of Common Terminology Criteria for Adverse Events (CTCAE) grade 3-5 toxicities overall and in three risk subgroups ("low-risk," "mid-risk" and "high-risk") determined by the Cancer and Aging Research Group-Breast Cancer (CARG-BC) tool.

II. Evaluate the accuracy of the CARG-BC tool in predicting the incidence of CTCAE grade 3-5 toxicities.

III. Determine the incidence of dose-reductions, dose-delays, treatment discontinuation and reduced-dose intensity (RDI; defined as < 85% of total dose) overall and in the three risk subgroups.

IV. Determine the incidence of hospitalizations overall and in the three risk subgroups.

V. To examine the effect of the intervention on quality of life overall and in the three risk subgroups, as assessed by the Functional Assessment of Cancer Therapy-Breast (FACT-B) and Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F).

VI. To examine the effect of the intervention on function overall and in the three risk subgroups.

VII. To examine the effects of the intervention on patient expectation and self-efficacy, as assessed by Outcomes Expectations for Exercise (OEE) and Perceived Self-Efficacy for Fatigue Self-Management (PSEFSM) respectively.

OUTLINE:

Patients participate in one-on-one coaching sessions with a health coach once a week (QW) to discuss the content offered in the program, and challenges they are currently facing in achieving their exercise goals. Patients receive a copy of the Walk with Ease Program (WWE) workbook, wear a fitness tracker and are encouraged to achieve 150 minutes of walking per week during chemotherapy and up to 1 month after chemotherapy. Patients also participate in the Growing Stronger Strength Training Program and receive instruction manuals. They perform the initial 2 exercises 2 days per week for 4 weeks, and subsequent 2 exercises 2 days per week for the remainder of the chemotherapy course. Patients maintain exercise logs and complete questionnaires over 30-45 minutes at baseline, end of chemotherapy and at 1 month after chemotherapy.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 65 years or older, female
  • Histologically confirmed Stage I, II or III breast cancer (if the patient has had more than one breast cancer, then the most recent diagnosis)
  • Scheduled to begin adjuvant or neoadjuvant chemotherapy regimen either as standard-of-care or on study
  • English or Spanish speaking
  • Able to provide written, informed consent
  • Patient-assessed ability to walk and engage in moderate physical activity
  • Willing and able to meet all study requirements

Exclusion criteria

  • The presence of significant medical conditions that in the physician's judgement preclude participation in the exercise intervention

Treatment and study plan

Discussion

Procedure

Participate in coaching sessions

Other names: Discuss

Exercise intervention

Other

Perform walking exercise

Informational intervention

Other

Receive WWE workbook and Growing Stronger Strength Training Program instruction manual

Medical Device Usage and Evaluation

Other

Wear fitness tracker

Quality-of-Life Assessment

Other

Complete questionnaires

Other names: Quality of Life Assessment

Questionnaire Administration

Other

Complete questionnaires

Primary outcomes

  1. Adherence

    Time frame: Up to 1 month after chemotherapy

    Will be calculated as the ratios of (a) the average number of exercise sessions completed weekly to total number of weekly targeted sessions during the period of chemotherapy (goal = 5 for walking sessions and 2 for upper-extremity exercises wearable. The mean adherence will be calculated for each patient.

  2. Compliance

    Time frame: Up to 1 month after chemotherapy

    Compliance will be calculated as the ratio of the average total number of valid days (>= 10 hours /day of use) to the total number of weekly targeted days (goal = 5). The mean compliance will be calculated for each patient.

  3. Retention

    Time frame: Up to 1 month after chemotherapy

    Will be assessed as the proportion of patients who enrolled in the study who complete all questionnaires and assessments at all time points.

Secondary outcomes

  1. Incidence of adverse events (AEs)

    Time frame: Up to 1 month after chemotherapy

    Chemotherapy toxicity will be measured per Common Terminology Criteria for Adverse Events version 5.0. All AEs (grade 1-5) will be captured at each follow-up visit during chemotherapy.

  2. Geriatric assessment

    Time frame: Baseline up to 1 month after chemotherapy

    The Wilcoxon signed rank test will be used to assess the changes of geriatric assessment measures.

  3. Short Physical Performance Battery (SPPB)

    Time frame: Baseline up to 1 month after chemotherapy

    The Wilcoxon signed rank test will be used to assess the changes physical performance (SBBP).

  4. Quality of life questionnaires

    Time frame: Baseline up to 1 month after chemotherapy

    Assessed using Functional Assessment of Cancer Therapy-Breast and Functional Assessment of Chronic Illness Therapy-Fatigue. The Wilcoxon signed rank test will be used to assess the changes of quality of life measures.

  5. Outcome Expectations for Exercise (OEE) Scale Questionnaires

    Time frame: Baseline up to 1 month after chemotherapy

    The Wilcoxon signed rank test will be used to assess the changes of expectations for exercise (OEE) within patient from baseline to each follow-up time point. Scale 1 (Strongly Disagree) to 5 (Strongly Agree)

  6. Perceived Self-Efficacy for Fatigue Self-Management (PSEFSM) questionnaires

    Time frame: Baseline up to 1 month after chemotherapy

    The Wilcoxon signed rank test will be used to assess the changes self-efficacy for fatigue (PSEFSM) within patient from baseline to each follow-up time point. PSEFSM 35-36 is a 6-item scale that uses a 10-point response option ranging from "not at all confident" to "total confident.

Sponsors and collaborators

Lead sponsor

M.D. Anderson Cancer Center

Other

Registry information

Official study title

The EXCitE Study: Exercise During Chemotherapy in Older Women With Early-Stage Breast Cancer

Important dates

Study start
2020
Primary completion
2026
Study completion
2026
First posted
Aug 27, 2021
Registry last updated
Mar 5, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.